健帆生物
(300529)
| 流通市值：111.97亿 | | | 总市值：174.50亿 |
| 流通股本：5.12亿 | | | 总股本：7.99亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 547,835,977.14 | 2,677,320,710.76 | 2,195,690,243.92 | 1,495,624,529.8 |
| 营业收入 | 547,835,977.14 | 2,677,320,710.76 | 2,195,690,243.92 | 1,495,624,529.8 |
| 二、营业总成本 | 331,034,826.7 | 1,711,410,834.56 | 1,282,068,331.55 | 861,393,672.66 |
| 营业成本 | 105,537,949.67 | 514,607,933.6 | 410,333,473.21 | 291,105,613.64 |
| 税金及附加 | 9,174,764.04 | 43,071,407.11 | 35,054,795.5 | 23,972,478.38 |
| 销售费用 | 113,927,136.54 | 691,993,102.56 | 510,257,725.2 | 340,764,543.02 |
| 管理费用 | 38,464,083.02 | 189,201,207.13 | 128,708,141.07 | 84,668,750.75 |
| 研发费用 | 52,980,606.72 | 240,093,157.22 | 174,715,744.33 | 112,785,154.32 |
| 财务费用 | 10,950,286.71 | 32,444,026.94 | 22,998,452.24 | 8,097,132.55 |
| 其中:利息费用 | 14,239,123.88 | 63,713,298.39 | 47,947,089.05 | 32,560,826.4 |
| 其中:利息收入 | 3,281,412.36 | 30,996,382.57 | 26,133,443.83 | 24,543,477.7 |
| 加:公允价值变动收益 | 12,815,939.81 | 1,023,228.9 | 334,745.17 | 5,802,775.48 |
| 加:投资收益 | 619,349.89 | 42,089,876.63 | 24,694,421.65 | 8,179,293.09 |
| 资产处置收益 | -2,096,892.28 | 3,639,820.27 | 2,372,652.83 | 2,163,697.06 |
| 资产减值损失(新) | 395,252.56 | -10,843,712.79 | -15,321.9 | - |
| 信用减值损失(新) | 427,280.27 | -1,721,690.32 | -8,725,141.9 | -7,914,835.48 |
| 其他收益 | 7,543,591.49 | 45,268,375.99 | 52,078,282.13 | 34,521,804.09 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 236,505,672.18 | 1,045,365,774.88 | 984,361,550.35 | 676,983,591.38 |
| 加:营业外收入 | 22,825.48 | 207,090.86 | 107,093.06 | 99,454.3 |
| 减:营业外支出 | 11,399,090.81 | 38,608,677.82 | 29,849,134.39 | 16,830,487.49 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 225,129,406.85 | 1,006,964,187.92 | 954,619,509.02 | 660,252,558.19 |
| 减:所得税费用 | 36,952,099.5 | 192,777,811.13 | 165,792,667.72 | 109,496,807.52 |
| 六、净利润 | 188,177,307.35 | 814,186,376.79 | 788,826,841.3 | 550,755,750.67 |
| 持续经营净利润 | 188,177,307.35 | 814,186,376.79 | 788,826,841.3 | 550,755,750.67 |
| 归属于母公司股东的净利润 | 188,783,596.97 | 820,195,432.44 | 791,634,115.46 | 552,505,833.05 |
| 少数股东损益 | -606,289.62 | -6,009,055.65 | -2,807,274.16 | -1,750,082.38 |
| (一)基本每股收益 | 0.23 | 1.05 | 0.99 | 0.69 |
| (二)稀释每股收益 | 0.23 | 1.07 | 0.97 | 0.68 |
| 八、其他综合收益 | - | 1,054,450.84 | - | - |
| 归属于母公司股东的其他综合收益 | - | 1,054,450.84 | - | - |
| 九、综合收益总额 | 188,177,307.35 | 815,240,827.63 | 788,826,841.3 | 550,755,750.67 |
| 归属于母公司股东的综合收益总额 | 188,783,596.97 | 821,249,883.28 | 791,634,115.46 | 552,505,833.05 |
| 归属于少数股东的综合收益总额 | -606,289.62 | -6,009,055.65 | -2,807,274.16 | -1,750,082.38 |
| 公告日期 | 2025-04-16 | 2025-04-16 | 2024-10-19 | 2024-08-08 |
| 审计意见(境内) | | 标准无保留意见 | | |